KRAS and RASopathy: Our study allowed the expansion of the clinical spectrum of mosaic RASopathies and supports that somatic mosaicism for recurrent mutations in KRAS and FGFR1 is a commonly involved mechanism in these rare oculocutaneous developmental anomalies.